

Pharmacy and Therapeutics (P&T) Committee Meeting

Tuesday, May 22nd 2018, 6:30 p.m. to 8:00 p.m.

Agenda

Topic:

Presenter:

- | | |
|--|--|
| <p>1. Welcome</p> <ul style="list-style-type: none"> • Call to Order • Roll Call | <p>Carl Antolick III, Chair</p> |
| <p>2. Conflict of Interest Statement</p> | <p>Carl Antolick III, Chair</p> |
| <p>3. Minutes from February 20, 2018 Meeting*</p> | <p>Carl Antolick III, Chair</p> |
| <p>4. Old Business</p> <ul style="list-style-type: none"> • Formulary Development and Management at CVS Caremark • Plan Formulary Decisions <ul style="list-style-type: none"> ○ New Policies ○ Policy Removals | <p>Carl Antolick III, Chair</p> |
| <p>5. Formulary Updates*</p> <ul style="list-style-type: none"> • Hyperinflation Exclusions • Tier Changes <ul style="list-style-type: none"> ○ Uptier ○ Downtier • Formulary Additions • New Drug Reviews <ul style="list-style-type: none"> ○ Calquence® ○ Verzenio™ ○ Xermelo™ ○ Imfinzi® ○ Ozempic® ○ Trogarzo™ ○ Odactra™ ○ Symdeko™ | <p>Carl Antolick III, Chair</p> <p>Heather Renee Jarnigan, CVS</p> <p>Heather Renee Jarnigan, CVS</p>
<p>Michael Spiritos, MD</p> <p>Michael Spiritos, MD</p> <p>Michael Spiritos, MD</p> <p>Michael Spiritos, MD</p> <p>Jennifer Burch, PharmD</p> <p>John Engemann, MD</p> <p>Joseph Shanahan, MD</p> <p>David Konanc, MD</p> |
| <p>6. Utilization Management Policy Review*</p> <ul style="list-style-type: none"> • New Policies Under Consideration <ul style="list-style-type: none"> ○ Dupixent® Enhanced SGM ○ Eucrisa® ○ Topical Corticosteroids | <p>Carl Antolick III, Chair</p> <p>Heather Renee Jarnigan, CVS</p> |

- Existing Policies
 - Praluent®
 - Repatha®
 - Omega-3 Fatty Acids
 - Prolia®
 - Xgeva®

Heather Renee Jarnigan, CVS

7. Adjourn

Carl Antolick III, Chair

- Next Meeting: *Tuesday August 21, 2018 from 6:30 to 8:00 PM via webinar*